Harrow Health Acquires Rights To Novartis’ Five Approved Ophthalmic Products
Harrow Health Inc (NASDAQ:HROW) entered a binding agreement to acquire the exclusive U.S. commercial rights to five FDA‑approved ophthalmic products from Novartis…
A Career Politician Who Regularly Trades The SPY, Picked Up These 3 High Yielding ETFs Instead
Representative Robert Wittman (R-VA) is the vice-ranking member of the House Armed Services Committee and also serves on the Committee on Natural Resources.
Novartis Shares Detailed Results From Experimental Drug For Rare Blood Disorder
Novartis AG (NYSE:NVS) announced detailed results from the pivotal Phase 3 APPLY-PNH trial. The results showed that most of the paroxysmal…
Erasca Oulicenses Its Mid-Stage Cancer Program To Novartis, Raises $100M Via Equity Offering
Erasca Inc (NASDAQ:ERAS) has entered into an exclusive worldwide license agreement with Novartis AG (NYSE:NVS) for naporafenib, a Phase 2 pivotal-ready pan-RAF inhibitor…
Novartis’ Rare Blood Disorder Therapy Aces Second Late-Stage Trial
Novartis AG’s (NYSE:NVS) Phase 3 APPOINT-PNH study of iptacopan in complement-inhibitor-naïve adults with paroxysmal nocturnal hemoglobinuria (PNH) met its primary endpoint. …
Novartis Announced Investigational Iptacopan Provides Clinically Meaningful Increases in Hemoglobin Levels in Complement-inhibitor-naïve Patients With PNH
Novartis today announced the Phase III APPOINT-PNH study (NCT04820530) of investigational oral monotherapy iptacopan in complement-inhibitor-naïve (including anti-C5 therapies) adults with PNH met its primary endpoint1.
MorphoSys Shares Higher Premarket After Co Announced on Tuesday an Upfront Payment of $23M from Novartis for Exclusive Worldwide Rights for Pre-clinical Inhibitors of a Novel Cancer Target
MorphoSys announced on Tuesday, that its fully owned subsidiary Constellation Pharmaceuticals, Inc. has entered into a global licensing agreement with Novartis to research, develop and commercialize its pre-clinical inhibitors of a novel cancer target. This program was added to MorphoSys' research portfolio following its acquisition of Constellation Pharmaceuticals, Inc.
Novartis Announced Kisqali Prolonged PFS Benefit for Pre- and Perimenopausal Patients With Aggressive HR+/HER2− Metastatic Breast Cancer Compared to Chemotherapy
Novartis today announced results from the RIGHT Choice Phase II trial evaluating Kisqali® (ribociclib) plus endocrine therapy (ET) against combination chemotherapy (CT) in the first-line setting for pre- and perimenopausal patients with aggressive forms of hormone receptor-positive, human epidermal growth factor receptor-2 negative (HR+/HER2−) metastatic breast cancer (MBC), including patients wit
Novartis Announced Pluvicto Shows Statistically Significant and Clinically Meaningful Radiographic Progression-free Survival Benefit in Patients With Psma–positive Metastatic Castration-resistant Prostate Cancer
Today, Novartis announced the pivotal Phase III PSMAfore study with PluvictoTM (INN: lutetium (177Lu) vipivotide tetraxetan), a prostate-specific membrane antigen (PSMA)-targeted radioligand therapy, met its primary endpoint.
Mirati Plays Catch-Up With Amgen, Gilead’s 2nd Try With AIDS Drug, Cytokinetics’ Adcom Test And More: Key Nov FDA Decisions For Biotech Investors
Food and Drug Administration decisions and advisory committee verdicts slated for November were mostly positive. New molecular entity approvals so far this year trail 2021’s tally by about 35%.